Portage Biotech Inc Ordinary Shares PRTG 深 沪
已收盘 08-08 16:00:00 美东时间
9.30
-0.670
-6.72%
华盛通- 最 高10.06
- 今 开10.06
- 成交量 12.16万股
- 最 低 8.08
- 昨 收 9.97
- 总市值 2119.10万
- 52周最高 23.01
- 市盈率 静 --
- 换手率 5.33%
- 52周最低 2.30
- 委 比 -76.39%
- 总股本 227.86万
- 历史最高 899.52
- 量 比 1.29
- 振 幅 19.86%
- 历史最低 2.098
- 每 手 1
- 风险率 1.88%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Shares of Worthington Steel, Inc. (NYSE:WS) rose sharply in today's pre-market ...
06-26 17:12
Portage Biotech Regains Nasdaq Compliance
Portage Biotech Inc ( ($PRTG) ) has shared an update. On June 24, 2025, Portage...
06-25 19:49
Portage Biotech jumps 20%, regains Nasdaq compliance
Portage Biotech (NASDAQ:PRTG) received formal notice from Nasdaq that the company has evidenced compliance with all applicable requirements for continued listing. The company had previously received...
06-25 19:38
Portage Biotech Regains Full Compliance with Nasdaq Continued Listing Requirements
Portage Biotech Inc. announced that it has met all applicable requirements for continued listing on The Nasdaq Capital Market. The company, a clinical-stage immuno-oncology firm developing novel biologics to enhance the immune system's ability to fight cancer, received formal notice from Nasdaq on June 24, 2025. Portage Biotech aims to transform cancer treatment through its innovative pipeline. The company also noted that forward-looking statemen...
06-25 11:00
Portage Biotech And Compedica Entered A Mutual Subscription Agreement
Pursuant to the Subscription Agreement, Portage issued 625,000 ordinary shares at a per share price of $8.00 in exchange for 1,165,501 shares of Compedica with a value of $4.29 per share, in a transaction valued at
06-09 18:04
Portage Biotech and Compedica Stock-for-Stock Exchange
Portage Biotech and Compedica Holdings have entered a Subscription Agreement, with Portage issuing 625,000 shares worth $8 each for 1.165 million Compedica shares valued at $4.29 each, totaling $5 million. Compedica now owns 27.4% of Portage's shares. The partnership aims to support the development and commercialization of Compedica's OptiPulse medical device for treating diabetic foot ulcers, a market valued over $4 billion in the U.S. Compedica...
06-09 10:00
Portage Biotech Stock Surges As It Prepares For Human Trial
Portage Biotech stock jumped after new PORT-7 data showed enhanced immune response and plans advanced for combined A2A and A2B receptor blockade.
04-28 22:37
Market-Moving News for April 28th
PRTG: 81% | Portage Biotech Reports Confirmatory Preclinical Efficacy Data For PORT-7 (TT-4). The New Data In A Murine Mesothelioma Model Demonstrated Single-Agent Activity For PORT-7 That Was Superior To Treatment
04-28 19:28
Portage Biotech Announces Preclinical Success for PORT-7 in Mesothelioma
Portage Biotech Inc ( ($PRTG) ) has provided an announcement. On April 28, 2025...
04-28 18:27
Why Is Portage Biotech Stock Skyrocketing Friday?
Portage Biotech unveils new preclinical data on PORT-7, showing strong antitumor effects in mesothelioma and advancing plans for clinical trials.
03-29 01:13
